T-cell prolymphocytic leukaemia: Does the expression of CD8+phenotype justify the identification of a new subtype? Description of two cases and review of the literature

被引:10
作者
Ascani, S
Leoni, P
Orcioni, GF
Bearzi, I
Piccioli, M
Materazzi, M
Zinzani, PL
Gherlinzoni, F
Falini, B
Pileri, SA
机构
[1] Univ Bologna, Inst Haematol & Clin Oncol L&A Seragnoli, Serv Pathol Anat & Hematopathol, Bologna, Italy
[2] Univ Ancona, Umberto I Hosp, Chair Haematol, Ancona, Italy
[3] Univ Ancona, Umberto I Hosp, Inst Pathol Anat, Ancona, Italy
[4] St Maria Hosp, Immunohaematol & Transfus Ctr, Terni, Italy
[5] Univ Perugia, Inst Haematol, I-06100 Perugia, Italy
关键词
cytogenetics; peripheral T-cell lymphoma; phenotype; T-cell chronic lymphocytic leukaemia; T-cell prolymphocytic leukaemia;
D O I
10.1023/A:1008349422735
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
T-cell chronic lymphocytic leukaemia (T-CLL) has recently been reclassified under the heading of T-cell prolymphocytic leukaemia (T-PLL) because of its unfavourable clinical course, independently of the morphologic features. This rare neoplasm usually shows CD4+/CD8- phenotype. Herein we report on two cases of T-PLL with CD8 expression that correspond to a possible variant of the disease first proposed by Hui et al. in 1987. These cases presented with malignant cells showing immunophenotypic features that can be easily identified and distinguished from other peripheral T-cell leukemias. However, the total number of cases studied is inadequate for defining a discrete clinico-pathologic entity with characteristic clinical features and cytogenetical abnormalities. An international collaboration in which tissue from similar cases is referred to a central pathologist for immunophenotyping and cytogenetical study, and clinical data are centrally compiled, may assist in defining this rare malady as a discrete clinico-pathologic entity.
引用
收藏
页码:649 / 653
页数:5
相关论文
共 34 条
[11]  
HOYER JD, 1995, BLOOD, V86, P1163
[12]   NEW AGGRESSIVE VARIANT OF SUPPRESSOR CYTOTOXIC T-CLL [J].
HUI, PK ;
FELLER, AC ;
PILERI, S ;
GOBBI, M ;
LENNERT, K .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (01) :55-59
[13]   SUPERIORITY OF PROMACE-CYTABOM OVER PROMACE-MOPP IN THE TREATMENT OF ADVANCED DIFFUSE AGGRESSIVE LYMPHOMA - RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL [J].
LONGO, DL ;
DEVITA, VT ;
DUFFEY, PL ;
WESLEY, MN ;
IHDE, DC ;
HUBBARD, SM ;
GILLIOM, M ;
JAFFE, ES ;
COSSMAN, J ;
FISHER, RI ;
YOUNG, RC .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :25-38
[14]  
LOUGHRAN TP, 1988, BLOOD, V71, P822
[15]  
LOUGHRAN TP, 1987, BLOOD, V69, P72
[16]  
MATUTES E, 1991, BLOOD, V78, P3269
[17]   MATURE T-CELL LEUKEMIAS AND LEUKEMIA LYMPHOMA SYNDROMES - REVIEW OF OUR EXPERIENCE IN 175 CASES [J].
MATUTES, E ;
CATOVSKY, D .
LEUKEMIA & LYMPHOMA, 1991, 4 (02) :81-91
[18]   THE MORPHOLOGICAL SPECTRUM OF T-PROLYMPHOCYTIC LEUKEMIA [J].
MATUTES, E ;
TALAVERA, JG ;
OBRIEN, M ;
CATOVSKY, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (01) :111-124
[19]  
MATUTES E, 1993, LEUKEMIA, V7, P917
[20]  
PANDOLFI F, 1984, CANCER, V53, P445, DOI 10.1002/1097-0142(19840201)53:3<445::AID-CNCR2820530313>3.0.CO